Clinical trials: End of Life
Cardiac Arrest, Sudden Cardiac Death
Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial
The purpose of this research study is to evaluate the effectiveness of metoprolol, a "beta blocker," in treating patients in the hospital with a cardiac arrest. It will be given intravenously (given into a vein).
- Conditions
- Cardiac Arrest, Sudden Cardiac Death, Ventricular Fibrillation, Tachycardia, Ventricular
- Trial name
- Shock n Block (NCT00401882)
- Testing
- Epinephrine, Metoprolol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- David Haines, MD
Squamous Cell Carcinoma of Head and Neck
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M…
- Trial name
- NCT04489888
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 101 people
- Sponsor
- Merck Sharp & Dohme LLC
Mucopolysaccharidosis I, Mucopolysaccharidosis II
Clinical Trial of Growth Hormone in MPS I, II, and VI
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
- Trial name
- NCT00748969
- Testing
- Somatropin (DNA origin)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Liver Transplantation, Kidney Transplantation
Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death.
- Trial name
- NCT01197573
- Testing
- rTPA Treatment, No TPA Treatment
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- The Cleveland Clinic
Pancreatic Cancer
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the…
- Trial name
- NCT00521404
- Testing
- CS-1008 (humanized anti-DR5 antibody), gemcitabine
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Metastatic Colon Cancer, Solid Tumor
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
The main purpose of this study is to determine the dose of poly-ICLC that is safe and tolerable when it is combined with pembrolizumab in patients with colon cancer.
- Trial name
- NCT02834052
- Testing
- pembrolizumab, Poly-ICLC
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Asha Nayak
Advanced or Metastatic Solid Tumors
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult…
- Trial name
- NCT05594043
- Testing
- MK-6598, Pembrolizumab
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Heart Rate Response to Regadenoson and Sudden Cardiac Death
The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
- Trial name
- NCT01842035
- Testing
- regadenoson
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Alabama at Birmingham
Cardiovascular Events
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood…
- Trial name
- APOLLO (NCT01259297)
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 185 sites in United States, Argentina and 16 more
- Volunteers
- 2,336 people
- Sponsor
- Novartis Pharmaceuticals
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Discrimination, Racial, Communication
PRISM Race and Communication Pilot RCT
This is a pilot randomized trial of 60 patients to test feasibility, acceptability and efficacy of PRISM to improve resilience and facilitate improved patient-clinician communication in racially minorities patients with serious…
- Conditions
- Discrimination, Racial, Communication, Chronic Illness, Bias, Racial
- Trial name
- NCT04915079
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Cardiomyopathy, Dilated, Arrhythmia
Mental Stress Reduction in Defibrillator Patients
The purpose of this study is to assess the effectiveness of a 10 week program of Stress Management versus control Patient Education sessions on cardiac responses to mental stress in veterans with Implantable…
- Conditions
- Cardiomyopathy, Dilated, Arrhythmia, Anger, Stress
- Trial name
- NCT00624520
- Testing
- Cognitive Behavioral Stress Management (CBSM), Patient Education
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- US Department of Veterans Affairs
Advance Care Planning
Culturally Tailoring an Advance Care Planning Intervention for American Indians
This project has three specific aims: (1) culturally tailor the content of the Make Your Wishes about You (MY WAY) ACP curriculum and guide for one American Indian tribe; (2) assess the feasibility of the culturally-tailored MY…
- Trial name
- NCT05304117
- Testing
- Advance Care Planning
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Western Carolina University
Infant Mortality, Preterm Birth
Antenatal Micronutrient Supplementation and Infant Survival
The purpose of this community-based randomized trial is to examine whether a daily antenatal and postnatal multiple micronutrient supplement given to women will enhance newborn and infant survival and health and other birth…
- Conditions
- Infant Mortality, Preterm Birth, Low Birth Weight, Neonatal Mortality
- Trial name
- JiVitA-3 (NCT00860470)
- Testing
- Iron (27 mg) - folic acid (600 ug), Multiple micronutrient
- Where
- 2 sites in United States, Bangladesh
- Volunteers
- 44,567 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatocellular Carcinoma
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or…
- Trial name
- NCT03867084
- Testing
- Pembrolizumab
- Where
- 249 sites in United States, Argentina and 29 more
- Volunteers
- 959 people
- Sponsor
- Merck Sharp & Dohme LLC
Sudden Cardiac Death, Bradycardia
REASSURE AV Registry
Long term follow-up to monitor safety for patients implanted with a B301 ASSURE device.
- Trial name
- REASSURE (NCT01074034)
- Testing
- AV Therapy Assessment-B301 investigational device
- Where
- 36 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Scientific Corporation
Advanced/Metastatic Melanoma
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
This is a Phase 2 study to assess the efficacy, safety, and tolerability of gebasaxturev administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone…
- Trial name
- NCT04152863
- Testing
- Gebasaxturev IV, Gebasaxturev ITu, Pembrolizumab
- Where
- 30 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based…
- Trial name
- NCT03635567
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- 149 sites in United States, Argentina and 17 more
- Volunteers
- 617 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer (NSCLC)
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing systemic therapy.
- Trial name
- NCT01905657
- Testing
- Pembrolizumab, Docetaxel
- Volunteers
- 1,034 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors.
- Trial name
- NCT02862457
- Testing
- Epacadostat 25 mg, Epacadostat 100 mg, pembrolizumab 200 mg
- Volunteers
- 34 people
- Sponsor
- Merck Sharp & Dohme LLC